KYNU

Across TCGA pan-cancer cohorts, KYNU mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KYNU data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher KYNU mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KYNU expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, HNSC, and GBM are the cancer types where KYNU mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.681	0.843	.001	43	view →
HNSC	DFS	Tertile	III,IV	0.417	0.736	.003	17	view →
GBM	OS	Quartile	All	0.220	0.592	.002	10	view →
CCRCC	DFS	Median	II,III,IV	0.940	0.796	.016	8	view →
LSCC	OS	Median	II,III,IV	0.688	0.882	.022	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KYNU–PDAC (DFS)

Open the PDAC breakdown →